UNSPSC 51283304: Cycloserine tartrate

This classification denotes an antitubercular agent with the molecular formula C4H6O6.C3H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24EZ3L1E6S. Most nations, for tariff and trade purposes, schedule cycloserine tartrate under HS 29419000. As of Q4 2014, CYCLOSERINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C1[C@H](C(=O)NO1)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51283304 Cycloserine tartrate is a Commodity code with minimal alignment to recent state and local procurement activity. The code nominally describes a single pharmaceutical compound, but recent opportunities tagged under it actually solicit naloxone and safe drug deactivation systems, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing — a significant scope divergence. State and local buyers are soliciting under this code include county health departments (Seminole County, Florida), city fire departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP). The procurement mix ranges from direct purchase of naloxone and deactivation equipment for community health initiatives to manufacturer-direct contracts for pharmaceutical distribution networks and medical supply agreements for emergency services.

Recent activity appears across Florida, Texas, and Minnesota, with the most concrete opportunities being Seminole County's IFB for naloxone and drug deactivation systems with quarterly deliveries, the City of Tampa's bid for medical and first aid supplies supporting its Fire Department Rescue Division (estimated $700,000, response deadline March 13, 2026, designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount), and Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (response deadline March 26, 2026) serving state and local government facilities across Minnesota and Oregon. The Texas HHS Commission also issued an RFI on direct-to-manufacturer prescription programs (response due April 3, 2026) to inform future procurement strategy for pharmacy benefit programs. The code's recent opportunities do not appear to involve cycloserine tartrate directly; the tagging reflects a pharmaceutical classification mismatch rather than active procurement under the nominal commodity.